Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 10 - 18 save search
Adamis Receives FDA Approval for ZIMHINew High-Dose Naloxone Product for the Treatment of Opioid Overdose
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 23.01%
H: 6.47%
C: -11.51%
treatment fda opioid fda approval approval
FDA Serves Omeros, MannKind-United and Revance with CRLs
Published: 2021-10-18 (Crawled : 15:00) - biospace.com/
OMER | $3.08 0.0% 210K
|
Health Technology
|
| O: -21.64%
H: 0.49%
C: -7.35%
MNKD | $4.15 0.97% 0.96% 1M
|
Health Technology
|
| O: -18.08%
H: 0.69%
C: -4.37%
fda
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Published: 2021-10-18 (Crawled : 14:00) - biospace.com/
RNA | News M | $25.12 3.97% 3.82% 860K
|
Health Technology
|
| O: -0.28%
H: 3.54%
C: -4.94%
treatment fda fast track fast track designation granted grant designation
FDA Authorizes New Saliva Sample Collection Method for High-Throughput, Automated COVID-19 Testing System
Published: 2021-10-18 (Crawled : 14:00) - biospace.com/
TMO | News | $574.59 4.78% -1.12% 2.5M
|
Health Technology
|
| O: 0.58%
H: 1.26%
C: 0.77%
covid saliva fda test covid-19
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
Published: 2021-10-18 (Crawled : 14:00) - enochianbio.com
ENOB 4 | $0.7 0.0% 88K
|
Health Technology
|
| O: 0.0%
H: 6.13%
C: 4.63%
fda potential hiv
FDA Action Alert: Omeros, Oyster Point, BeiGene and Ocular
Published: 2021-10-18 (Crawled : 14:00) - biospace.com/
OMER | $3.08 0.0% 210K
|
Health Technology
|
| O: -21.64%
H: 0.49%
C: -7.35%
fda ocular
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
Published: 2021-10-18 (Crawled : 12:00) - biospace.com/
OMER | $3.08 0.0% 210K
|
Health Technology
|
| O: -21.64%
H: 0.49%
C: -7.35%
treatment fda application license response
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
Published: 2021-10-18 (Crawled : 10:00) - prnewswire.com
OYST | $11.17 0.18% -0.27%
|
Health Technology
|
| O: 9.77%
H: 2.68%
C: -7.29%
dry eye disease nasal spray treatment fda eye fda approval eye disease approval
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.